Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers

Targeting anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase receptor initially identified as a potent oncogenic driver in anaplastic large-cell lymphoma (ALCL) in the form of nucleophosmin (NPM)-ALK fusion protein, using tyrosine kinase inhibitors has shown to be a promising therapeutic a...

Descripción completa

Detalles Bibliográficos
Autor principal: Alshareef, Abdulraheem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704166/
https://www.ncbi.nlm.nih.gov/pubmed/29143801
http://dx.doi.org/10.3390/cancers9110148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704166/
https://www.ncbi.nlm.nih.gov/pubmed/29143801
http://dx.doi.org/10.3390/cancers9110148

Ejemplares similares